Abstvuct-Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension m Dahl salt-sensitive (Dahl S) rats To determine if this also occurs with other antlhpldemlc agents, we compared the effects of a related drug, fenofibrate, with those of an unrelated agent, pravastatm, on blood pressure, renal histology, and P4504A activity Dahl S rats were pretreated with fenofibrate (95 mg/kg per day), pravastatm (70 mg/kg per day), or vehicle for 7 days before and after bemg switched from a low-salt (0.1% NaCl) to a high-salt (8 0% NaCl) diet. After 3 weeks on the high-salt diet, mean artenal pressures averaged 183+13 (n=9), 126+10 (n=9), and 148% 11 mm Hg (n=8), respectively, m vehicle-, fenofibrate-, and pravastatm-treated animals Both drugs reduced the degree of protemurla and glomerular injury P4504A protein levels and the synthesis of 8,11, were increased m the liver and kidney of fenofibrate-treated, but not pravastatm-treated rats We also administered these agents to Dahl S rats m which hypertension had previously been induced by a high-salt diet Mean arterial pressures averaged 164+ 10, 113+23, and 160+ 15 mm Hg m rats treated with vehicle, fenofibrate, or pravastatm for 3 weeks Fenofibrate-treated rats exhibited a natrmresls Protemuna and glomerular injury were reduced by pravastatm but not by fenofibrate These results indicate that fenofibrate prevented the development of hypertension and reduced subsequent glomerular injury m Dahl S rats, probably secondary to increased renal production of 20-HETE Although pravastatm did not induce renal P4504A activity m these animals, it reduced the seventy of hypertension and renal damage through some other mechanism (Hy~evtension.
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Key Words: salt sensltlvlty n cytochrome P450 m hydroxyelcosatetraenolc acids n glomerulosclerosls n antlhpldemlc drugs w pravastatm n fenofibrate T he Dahl S rat IS the most widely studied genetic model of salt-sensmve hypertension ' When these animals are fed a high-salt diet, mean arterial pressure typically increases by 20 mm Hg within 24 hours and continues to nse to a plateau of 170 mm Hg or higher, around 2 weeks '-' The mltlal rise m artenal pressure appears to be tnggered by sodium retention The ammals gain about 7% m body weight; plasma volume and cardiac output mcrease slgmficantly * Later, cardiac output returns toward control values, and the hypertension IS mamtamed by increased penpheral vascular resistance 4
Previous studies have indicated that the pressure-natnuretlc relation 1s reset to a higher level of renal perfiuslon pressure m Dahl S rats 5 ' This resetting IS largely due to a marked elevation in sodium reabsorption m the thick ascending limb of the loop of Henle5,"" and IS associated with a deficiency of the production of 20-HETE,"' which IS a potent inhibitor of Na+,K+,2Ci-cotransport m this segment of the nephron " Indeed, exogenous admmlstratlon of 20-HETE has been reported to normalize chloride transport m the loop of Henle of Dahl S rats, and mhlbltors of 20-HETE formation increase loop chloride transport m Dahl salt-resistant rats ') Moreover, blockade of renal medullary 20-HETE synthesis by chronic renal medullary interstitial mfi~slon of 17-octadecynolc acid induces hypertension m normotenslve Lewis rats " Clofibrate belongs to the class of lipid-lowenng agents often called "fibrates," whch stimulate the peroxlsome prollferator activated receptor and Induce genes codmg for P4504A enzymes m the hver and ladney " Adnumstrahon of clofibrate to Dahl S rats Increases the synthesis of 20-HETE 111 the ludney and prevents the development of hypertension l4 However, the mechanism by which clofibrate lowers artenal pressure has not been deterrmned, and It remams to be seen whether the antlhypertenslve effect IS restricted to agents that induce the formation of 20-HETE or IS a general property of anthpldenuc agents The present study exanuned this question by studymg the effects of the peroxlsome prohferator activated receptor agonist, fenofibrate, and an unrelated antipldenuc agent, pravastatm, on blood pressure, renal P4504A achvq, renal histology, and protemuna m Dahl S rats before and a&er exposure to a high-salt &et of rats of both sexes were assigned to either the prevention study, m which drug therapy was begun before the switch from a low-Fait to a high-Talt &et or a treatment study, m which the drugs were started after 2 weeks of a lugh-salt &et
Methods

Prevention Study
The ammals were divided into three groups One group was gwen vehicle, connshng of Na&O, (20 mmol/L) and 0 3% &methyl sulfo~de and Tween-20 m the dnnkmg water The other groups received either fenofibrate 0 7 mmol/L (250 mg/L) or pravastahn 0 6 mmol/L (200 mg/L) In the vehicle After 1 week of treatment, the &et was changed to 8%NaCI (by we&), and dmg treatment was contmued for 3 ad&hond weeh
Treatment Protocol
After rats were fed the high-salt &et for 2 weeks, velncle, fenofibrate, or pravastatm was substituted for tap water, and the high-salt &et waq continued for a further 3 weeks Phenotyping After 3 weeks of drug treatment m either protocol, rats were anesthetized with ketamme (20 mg/kg IM) and thiobutabarbltal (50 mg/kg IP) A femoral artery was cannulated for direct measurement of arterial pressure, and a blood sample was collected for measurement of plasma cholesterol, tnglycende, and creatmme concentrations At the end of the experiment, the left kidney and a sample of hver were removed, weighed, and fixed m buffered 10% formalm for histological assessment of the degree of glomerular and vascular damage The right kidney and a piece of hver were also collected, frozen m hquld mtrogen, and then stored at -80°C for later measurement of arachldomc acid metabolism and P4504A protem levels Four to five rats from each of the groups underwent studies m metabolic cages (Nalgene Nunc International) Prevention study ammalc underwent two consecutive 24-hour urine collections, 10 to 14 days after the change to the 8% NaCl diet The treatment study rats had two conseLutlve 24-hour collections at 12 to 16 days after drug therapy was begun (4 to 5 weeks after the start of the high-salt diet) Fmally, four additional animals were placed m metabolic cages, 2 weeks after being given the high-salt diet, for sodium balance studies After three comecutwe 24-hour urme collections for sodnun, they were gtven fenofibrate m the drmkmg water, and four more consecunve 24-hour urme samples were collected Sochum Intake was estimated by the weight of food consumed and subtracted from the urmary sochum excretion to obtam the dally balance
Analytical Methods
Plzma cholesterol concentration was measured Fpectrophotometncally with an enzymaac assay previously described by Allam et al 'I' Plasma tnglycende concentrahon was measured usmg an enzymanc procedure " Plasma creatmme concentrations were measured using the modlficanon of the Jaffe color reaction previously described by Jemegard and TlderStrom 's Urinary protein concentration was measured usmg the Bradford method'" ucmg bovme serum albunun as a standard Unne sodmm concentration was ascertained by flame photometry Histological Analysis L.nzer and kidney samples from each group wele fixed m 10% buffered form&n, embedded m par&in, sechoned, and stamed with hematoxyhn and eosm or PAS, respechveiy Approxtmately 80 glomemh from each sagttal kidney section were exanuned using a hght nucroscope at 400 power The percentage of the mesangmm and glomerular capillary area filled mth PAS-positive material was Fcored on a five-pomt scale-0 (normal), 1 (0% to 25%), 2 (26% to 50%). 3 (51% to 75%). or 4 (76% to lOO%)accordmg to methods described by Kaslske et al 'I1 A morphomemc method described by Lee" W;~F used to eshmate the degree of vascular hypertropy m renal artenoles Typ~ally, wall thickness and lumen area were measured m 30 to 60 vessels, with outer dlametels between 30 and 150 pm, m each section usmg a video Imagmg Fystem and Image-l software (Universal Imagmg Corp) A hne was traced over the mner dashc lamma and outer boundary of the medlal layer, and the length and areas circumscribed by both hneq were determined Wall/ lumen area rahos were calculated ti-om these areas Glomerular sze was measured with the same system P4504A2 Protein Levels and Enzyme Activity Mlcrosomes from renal cortex, outer medulla, and hver tissue samplec were prepared as described prevtously 'I' Total protem COnCCntt'ahOn uac measured ucmg the Bradford'" method using bovmr y-globuhn ac standard Ahquots of nucrosomal protein (10 to Pravastatin and fenofibrate also had significant effects on the structure of preglomerular arterioles (Fig 3) . Interlobular and afferent arterioles of pravastatn-treated rats had thinner walls than those from rats m the other two groups. Wall/lumen area ratios were lower m pravastatin-treated animals ( Table 2 ).
CYP4504A
Protein Expression and Activity In preliminary studies, we found that pravastatin and fenofibrate treatment produced similar changes m CYP4504A protein concentration and enzyme activity in rats in the treatment and prevention protocols. Therefore, the results from both groups were combmed and are presented together in Fig 4. Representative lmmunoblots of protein extracted from the hver and kidney of vehicle and drug-treated ammals are presented m Fig 4a and 4b . CYP4504A protem levels were markedly induced m the renal cortex and liver of fenofibratetreated rats (Fig 4a, 4c, and 4e ), but were not sigmficantly different from control m rats treated with pravastatm (Fig 4b,  4c ,and 4e). CYP4504A protein levels also tended to be higher in the outer medulla of fenofibrate-treated than vehicle-treated rats, but this difference did not reach statistical significance (4d). CYP4504A enzyme activity was assessed by measuring 20-HETE production in renal and hepatic microsomes incubated with arachidonic acid and is shown in Fig 5. The production of 20-HETE was significantly greater in the renal cortex and liver of rats treated with fenofibrate than in control animals or pravastatin-treated rats. Mean renal medullary 20-HETE production was greater in fenofibrate-treated rats than in the other two groups, but this difference cvas not statistically significant. Pravastatin had no effect on 20-HETE synthesis in either the liver or the kidney. a, lmmunoblots comparing CYP4504A protein concentrations in renal cortical microsomes in three control rats (lanes 1, 2, and 3) and three fenofibrate treated rats (lanes 4, 5, and 6). b, Renal cortical microsomes from three control rats(lanes 1, 2, and 3) and three pravastatin treated rats (lanes 4, 5, and 6). Lane 7 in both a and b contained liver mrcrosomes from a clofibrate-treated SpragueDawley rat. CYP4504A protein levels in the liver and renal cortex. Furthermore, the activity of CYP4504A enzyme, as measured by the conversion of arachidomc acid to 20-HETE was also increased in nncrosomes prepared from the liver and the kidney of the fenofibrate-treated rats. 20-HETE Inhibits Na-K-ATPase actrvlty" " and sodium reabsorption in the proxunal tubule. Elevations m 20-HETE formation have recently been suggested to mediate the natrmretlc effects of angiotensm II, parathyroid hormone, and dopamme m this segment of the nephron.a4*' 20-HETE also inhibits chloride transport m the thick ascending loop of Henle" by blockmg a 70 pS potassium channel'" required for the recychng of potassium and the operation of the Na+,K+,2Cll cotransporter. Thus, an explanation for the present findings is that fenofibrate mcreases the renal production of 20-HETE, which, m turn, mhibits sodium reabsorption. Our recent finding that sodium excretion and the pressure-natriuretic response is nomrahzed by clofibrate"' is consistent with this notion. Treatment study rats receivmg fenofibrate gained less weight over the course of the study as than did the vehicle-and pravastatm-treated rats and also exhibited a natnuresic. Nevertheless, more carefully controlled balance studies will have to be performed before one can conclude that the antihypertensive action of fenofibrate m Dahl S rats with established hypertension is related to a diuretic action. 'The effect ofpravastatm to reduce blood pressure in Dahl S rats in the prevention shady was unexpected. Unlike fenofibrate, pravastatm did not increase CYP4504A expression or acnvlty in either the ltver or the kidney. Moreover, rats receiving pravastatm gamed amounts of weight equivalent to the control rats. We considered the possibility that the anhhypertensive effect ofpravastann could be explained by its annhpidemic action even though total plasma cholesterol and tnglycende concenhahons were not reduced. Oxrdized LDLs have been shown to impair endothehal function and alter vascular reachvity.B Reducing LDL cholesterol concentration in hyperlidemic humans can improve endothehal firncnon.B However, it 1s unlikely that -3 -2 -1 0 1 2 3 4 days after fenofibrate Figure  6 . Effect of fenofibrate on cumulatrve sodrum balance In rats previously made hypertensrve with an 8% NaCl dret.
changes in the ratio of HDL to LDL cholesterol could contribute to the changes in blood pressure seen in the present study since total cholesterol concentranon was relatively low and, nr our prelnnmaiy work, we found that >85% of cholesterol is in the form of HDL cholesterol in our strain of Dahl S rats. Our finding confirm a previous report by O'Donnell et al" that lovastahn prevented the development of hypertension in Dahl S rats in the absence of any effect on total, LDL, very low density lipoprotein, or HDL cholesterol levels.3" 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors such as pravastatm not only reduce the synthesis of cholesterol but also inhibit the formatron of ubiqumones, heme A, dohchol pyrophosphate, and isoprenoids." It is possible that reduced amounts of the latter compounds might contribute to the antlhypertensive effect of pravastatm. Isoprenoids such as farnesol and geranylgeramol combine with many types of proteins mvolved m signal transduction. Among the many proteins undergomg isoprenylation are rug and ros-hke small G-protemc. In particular, rus can increase smooth muscle responsiveness to increased intracellular calcium'2 and, perhaps more importantly, it is a key player in the tyrosine lunate-mediated growth-signalmg pathway mvolved in the proliferation of vascular smooth muscle and other cell types." Indeed, a consistent finding throughout the present study is that pravastatm markedly reduced the wall/lumen ratio of preglomerular renal arterioles. The antiproliferative effects of pravastatin may ameliorate some of the further use m blood pressure associated with changes m renal vascular resistance that accompany hypertrophy ofresistance vessels. The recent report by Jiang and Roman" from our laboratory, mdicatmg that chronic treatment with lovastatm markedly reduced hypertrophy of preglomerular arterioles, nnproved the pressure natnuresis response, and prevented the development of hypertension 11~ spontaneously hypertensive rats, 1s consistent with this formulation.
Regardless of the mechamsm of action, the Important new finding in the present study is that pravastatm did partially amehorate the development of hypertension m Dahl S rats and reduced the degree of glomerular damage. In the treatment studies ofDah1 S rats with preexisting hypertension, pravastatin had no effect on blood pressure, although we cannot rule out a small antihypertensive effect. Despite the fact that pravastatin
